⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
XCUR News
Exicure, Inc. Common Stock
Form 8-K
sec.gov
XCUR
Form 8-K
sec.gov
XCUR
Summary Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions
globenewswire.com
XCUR
Form 8-K
sec.gov
XCUR
Form 8-K
sec.gov
XCUR
Exicure, Inc. Reports Full Year 2025 Financial Results
globenewswire.com
XCUR
Exicure, Inc. Reports Full Year 2025 Financial Results
globenewswire.com
XCUR
Exicure Announces Publication in Annals of Hematology Highlighting Rapid Stem Cell Mobilization with Burixafor in Patients with Multiple Myeloma and Lymphoma Undergoing Transplant
globenewswire.com
XCUR
Exicure to Present Data from Burixafor Phase 2 Trial at the 2026 Tandem Meetings
globenewswire.com
XCUR
Flashpoint Therapeutics Appoints Venkat R. Krishnamurthy, Ph.D. as Chief Scientific Officer
businesswire.com
LLY
AZN
XCUR